Marc Elliott Lenburg

This inventor holds 13 USPTO granted patents and 9 published patent applications and 1 EPO patent. Top assignees: Boston University, The University of British Columbia, Health Research, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc Elliott Lenburg. Retrieved from https://idiyas.com/inventor/marc-elliott-lenburg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 9)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Berkeley, CA (US) (2018 - 2021)
Brookline, MA (US) (2017 - 2024)

Company Filing History:

The University of British Columbia

patents

1 out of 314

Health Research, Inc.

patents

4. 1 out of 1,429

The Brigham and Women's Hospital, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577620 - Nasal epithelium gene expression signature and classifier for the prediction of lung cancer (2026-03-17),

2. 12329771 - Methods relating to lung cancer (2025-06-17),

3. 12329759 - Methods and compositions relating to lung function (2025-06-17),

4. 11946928 - Methods and compositions relating to airway dysfunction (2024-04-02),

5. 11579140 - Methods related to bronchial premalignant lesion severity and progression (2023-02-14),

6. 11426423 - Methods relating to lung cancer (2022-08-30),

7. 10927417 - Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions (2021-02-23),

8. 10808285 - Diagnostic for lung disorders using class prediction (2020-10-20),

9. 10632140 - Methods relating to lung cancer (2020-04-28),

10. 10314855 - Methods relating to lung cancer (2019-06-11),

11. 10233498 - Therapeutic agent for emphysema and COPD (2019-03-19),

12. 9920374 - Diagnostic for lung disorders using class prediction (2018-03-20),

13. 9585930 - Therapeutic agent for emphysema and COPD (2017-03-07),

Title: **Marc Elliott Lenburg: Innovator in Respiratory Disease Research**

Introduction

Marc Elliott Lenburg is a notable inventor based in Brookline, MA, who has made significant contributions to the field of respiratory disease research. With a total of 12 patents to his name, he has pioneered advancements in methods and compositions for the prognosis and treatment of respiratory ailments.

Latest Patents

Among his latest patents are innovative methods and compositions that relate to lung function, particularly focusing on diseases such as Chronic Obstructive Pulmonary Disease (COPD). His research emphasizes the prognosis and treatment of respiratory diseases through novel technologies. Additionally, he has developed methods related to lung cancer, enabling the detection, diagnosis, and treatment of this condition. These methods include assessing the expression levels of specific miRNAs, which can lead to improved therapeutic strategies.

Career Highlights

Throughout his career, Marc Lenburg has been affiliated with prominent institutions, including Boston University and the University of British Columbia. His work in these research environments has underscored his commitment to advancing the understanding and treatment of lung diseases.

Collaborations

Lenburg has collaborated with esteemed colleagues such as Avrum Spira and Joshua David Campbell, contributing to the innovative research landscape in respiratory health. These partnerships have played a vital role in propelling his inventions and patents to the forefront of scientific discovery.

Conclusion

Marc Elliott Lenburg continues to be an influential figure in the realm of respiratory disease research. His numerous patents and collaborations reflect his dedication to improving patient outcomes and enhancing the scientific understanding of lung health. As he pursues further innovation, Lenburg’s contributions are likely to have a lasting impact in the field.

Profile summary based on public USPTO records.